MedImmune Expands Scientific and Engineering ... ( - Company also Establishes New Site L...)

MedImmune Expands Scientific and Engineering Leadership

Date:12/20/2007

- Company also Establishes New Site Leadership Team at Cambridge Facility -

GAITHERSBURG, Md., Dec. 20 /PRNewswire-FirstCall/ -- Continuing the solidification of its role as the global biologics unit for AstraZeneca plc (AZ), MedImmune today announced that Andrew D. Skibo has joined the company as senior vice president, engineering and JoAnn Suzich, Ph.D., a 19-year veteran of the company, has been promoted to vice president, research and development, infectious disease. In addition, MedImmune announced that it has established a new site leadership team at its Cambridge facilities as a part of the plan to integrate the former Cambridge Antibody Technology (CAT) organization into AZ's new global biologics unit, functioning under the name MedImmune.

"As MedImmune supports AZ in its efforts to build a major international presence in the research, development and manufacture of biological therapeutics, it's critical that we continue to expand the depth of our leadership capabilities," said David M. Mott, chief executive officer and president. "I am pleased with the high-caliber scientific and technical talent MedImmune continues to hire and retain as we strive to create the most productive and successful biotech business, with benefits to patients, shareholders and employees worldwide."

New Leadership

Andrew D. Skibo joins MedImmune as senior vice president, engineering. In this role he will be responsible for overseeing large-scale capital projects at all of MedImmune's facilities, including sites in California, Pennsylvania, Maryland, the Netherlands and the UK as well as the ongoing construction of the company's antibody-manufacturing facilities in Frederick, Maryland. He reports to Bernardus Machielse, Drs., executive vice president, operations. Previously, Mr. Skibo held the position of vice president, corporate engineering and capital projects at Amgen, Inc., responsible for restructuring and rebuilding the corporate engineering func
'/>"/>

SOURCE MedImmune
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
4. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
5. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
8. Rohm and Haas Expands in India
9. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
10. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
11. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors

Post Your Comments:

(Date:11/9/2009)...ina, Nov. 9 /PRNewswire-Asia/ -- Simcere Pharmaceu...ny"), a leading pharmaceutical company,specializin... of branded,generic and proprietary pharmaceutical...e the manufacturing license in China of Rosuvastat...Tianda"). The acquisition of the,manufacturing lic...

(Date:11/9/2009)... Lumension,s advanced device control capabilit...insider risk and quickly enhance their data securi...Scottsdale, AZ (PRWEB) Nov. 9, 2009 -- Lumension, ...y, today announced the general availability of Lu...enter (DCSC) to enable users to protect corporate...

(Date:11/9/2009)... Omnetics Connector Corporation announces that... certified. , Minneapolis...r Corporation, the leading manufacturer of miniatu...n, production and QA systems have been certified t..., International Quality System Standard., , ,The c...

(Date:11/9/2009)... Gifted young athletes are under increasing pressu...w Loyola University Health System study of 519 jun...ion increases the risk of injury. Researchers who ...ociation junior competition found that players who...thdraw from tournaments for medical reasons, typic...

(Date:11/8/2009)...lation would strengthen Medicare, improve coverage...wire-USNewswire/ -- SUMMARY: Yesterday the Unite...health care reform legislation that would strength...insurance companies that prices millions of Americ... Affordable Health Care for America Act (H.R. 3962...

Breaking Medicine News(10 mins):Health News:Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 2 Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 2 Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 3 Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 4 Health News:Omnetics Connector Corporation Achieves AS9100 Certification 2 Health News:Young tennis players who play only 1 sport are more prone to injuries 2 Health News:AARP NY Praises House Passage of Health Care Reform Bill 2 Health News:AARP NY Praises House Passage of Health Care Reform Bill 3 Health News:AARP NY Praises House Passage of Health Care Reform Bill 4

[0] Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin [0] Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance [0] Omnetics Connector Corporation Achieves AS9100 Certification [0] Young tennis players who play only 1 sport are more prone to injuries [1] AARP NY Praises House Passage of Health Care Reform Bill

... it,s worthwhile, expert says , , MONDAY, ...ors don,t seem to provide any particular benefit ...ds. , A defibrillator can provide a lifesaving ele...,s ability to pump blood nor does it help any life...

...mmon elective medical procedures , , EAGAN, Minn.... health care cost and quality information through ...oday by Blue Cross and Blue Shield of Minnesota. C...y information for dozens of common elective proced...

...- Hard to Treat Diseases (HTDS) www.htdsmedical.c...gators (lead by Professor Mirjana Stojiljkovic) fr...gical Research "Sinisa Stankovic", University of B...isease. The effectiveness of this therapy is shown...

...Eleanor Rogen of the University of Nebraska Medica... located in Omaha, Nebraska, have identified the t...ancer cells begin. Preventium http://www.preventi...esearch collaborator Eleanor Rogen, Ph.D. say: "We...

...o Medigap as Additional Coverage Option For Florid...SSEE, Fla., March 16 The National Kidney Foundati...d Altman and Representative Ritch Workman today fo...er age 65 who are facing challenges securing criti...

...ional, Inc.,(Nasdaq: DATA ), a technology and se...ns for the clinical trials industry, today announc...d full year of 2008. , Revenue for the fourth ...s ended December 31, 2008 compared to 48%,for the ...

Defibrillator May Not Help Many With Heart Failure Blue Cross Puts New Online Shopping Tool in Hands of Consumers Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple Sclerosis Preventium is 'where the prevention of breast and prostate cancer begins'The National Kidney Foundation of Florida Commends Senator Thad Altman, Representative Ritch Workman for Co-Sponsoring 'Common Sense' Legislation Widely Hailed as 'Good for Patients, Good for Taxpayers, Good for Florida'DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008

(Date:11/6/2009)...Call/ -- Boston Scientific Corporation (NYSE: BSX...t in principle with the U.S. Department of Justice... Guidant subsidiary in 2005. The alleged conduct ...fic,s 2006 acquisition of Guidant. ,, Boston Sc... by the U.S. Attorney,s Office in Minneapolis into...

(Date:11/6/2009)...- Philips Respironics applauds the efforts of the ...o raise awareness about an important public health...elease of the first-ever government study to monit...a milestone in quantifying the size and scope of t...ry leader and sleep therapy manufacturer, Philips ...

(Date:11/6/2009).../ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ), a b... small-molecule therapeutics for the treatment of ...), today reported recent accomplishments and finan... ended September 30, 2009. ,, (Logo: http://...,, "Since our last quarterly update, we have co...

[0] Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant [0] Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation [0] Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results

...SOUTH SAN FRANCISCO, Calif. and ALLSCHWIL, Switzer...today that data,published in The Lancet(1) show th...tension (PAH) patients (WHO functional class II - ...al deterioration by significantly,delaying time to...ents,worsening to WHO FC III/IV. A significant red...

...SYDNEY, Australia, June 19 /Xinhua-PRNewswire-Firs... announced that the company and the U.S. Food,and ...n the phase 3,registration trial of Bronchitol for...t process., The SPA process allows for FDA evalua... the primary basis of an efficacy claim in support...

Other Medicine Technology:Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 2 Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 3 Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 4 Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 5 Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 6 Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 2 Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 3

Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial

...seats and large backrests with lumbar support &bul... and casters and glides. • Choose the BE Seri...s including: industry, education, laboratory, clea...ull; With cast aluminum base • unit standard ...

BEC/1Q-ERB - Cast Aluminum Base - Model 1Q72-ERB

BET/1P-ERB - Tubular Base - Model 1P63

Medicine Products:

BEC/1Q-ERB - Cast Aluminum Base - Model 1Q64-R-ERB BEC/1Q-ERB - Cast Aluminum Base - Model 1Q53-R-ERB BEC/1Q-ERB - Cast Aluminum Base - Model 1Q72-ERB BET/1P-ERB - Tubular Base - Model 1P63

MedImmune Expands Scientific and Engineering ...( - Company also Establishes New Site L...),Health